Takeda has agreed to shell out about $1.177 billion for Japanese rights to 13 Amgen molecules, one of which is included as an option. Additionally, Takeda plans to acquire all the shares of Amgen’s Japanese subsidiary, Amgen KK.
Amgen retains certain copromotion rights in Japan on all programs. Takeda will pay $200 million in cash upfront. Amgen will also receive up to $340 million in expected worldwide development costs for these molecules over the next several years, $362 million in success-based milestone payments, and double-digit royalties on sales in Japan.
Takeda will also become Amgen’s worldwide partner for oncology candidate motesanib diphosphate. Amgen will obtain an additional $100 million upfront, $175 million in success-based milestones for the first two indications, and double-digit royalties on sales in Japan.
Motesanib diphosphate is currently in Phase II trial related to breast, non-small-cell, and thyroid cancers. Takeda will also pay 60% of ongoing clinical development expenses outside Japan and equally share profits outside the country.
“The development programs included in this collaboration represent the growth engine for Amgen in the next decade,” according to Amgen chairman and CEO, Kevin Sharer.
The deal includes early- to mid-stage candidates in oncology, inflammation, and pain. With the exception of motesanib diphosphate, all products included in the partnership are biologics.